MedTrace Logo

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

NCT00466752 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-11-22

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Studying samples of blood and tumor tissues in the laboratory from patients with prostate cancer may help doctors learn more about changes that occur in DNA after treatment with sorafenib tosylate

Conditions

  • Adenocarcinoma of the Prostate
  • Stage II Prostate Cancer
  • Stage III Prostate Cancer

Interventions

DRUG

sorafenib tosylate

Given PO

GENETIC

microarray analysis

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

gene expression analysis

Correlative studies

PROCEDURE

needle biopsy

Correlative studies

PROCEDURE

therapeutic conventional surgery

Undergo prostatectomy

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

western blotting

Correlative studies

GENETIC

RNA analysis

Correlative studies

Sponsors & Collaborators

Principal Investigators

  • Evan Yu · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-04-30
Completion
2011-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00466752 on ClinicalTrials.gov